Authors in this New England Journal of Medicine review article propose that because clinical trials are becoming more expensive and challenging to execute, researchers should consider the use of master protocols to evaluate more than one or two treatments in more than one patient type or disease within the same overall trial structure. The authors present examples from the study of cancer therapy, illustrating the variety of research objectives and trial designs used. They also highlight two types of trial innovations that are hallmarks of master protocols and they review considerations for use.
Read the full article in the NEJM.
Posted: Aug. 11, 2017